Hemab Therapeutics (NASDAQ:COAG) Rating Increased to Strong-Buy at The Goldman Sachs Group

The Goldman Sachs Group upgraded shares of Hemab Therapeutics (NASDAQ:COAG) to a strong-buy rating in a report issued on Tuesday morning,Zacks.com reports.

A number of other analysts have also recently issued reports on COAG. Wall Street Zen raised Hemab Therapeutics to a “hold” rating in a research report on Saturday, May 9th. Wedbush started coverage on Hemab Therapeutics in a research report on Tuesday. They issued an “outperform” rating and a $42.00 price objective for the company. Evercore started coverage on Hemab Therapeutics in a research report on Tuesday. They issued an “outperform” rating and a $50.00 price objective for the company. Finally, Jefferies Financial Group started coverage on Hemab Therapeutics in a research report on Tuesday. They issued a “buy” rating and a $39.00 price objective for the company. Two research analysts have rated the stock with a Strong Buy rating and two have issued a Buy rating to the company. Based on data from MarketBeat, Hemab Therapeutics has an average rating of “Strong Buy” and an average target price of $41.75.

Hemab Therapeutics Stock Performance

Shares of NASDAQ COAG opened at $27.84 on Tuesday. Hemab Therapeutics has a 52 week low of $23.00 and a 52 week high of $36.61.

Hemab Therapeutics (NASDAQ:COAG) last issued its quarterly earnings results on Thursday, May 21st. The company reported ($23.98) EPS for the quarter.

Insider Buying and Selling at Hemab Therapeutics

In other news, Director Ra Capital Management, L.P. bought 2,675,000 shares of the stock in a transaction dated Monday, May 4th. The shares were bought at an average price of $18.00 per share, for a total transaction of $48,150,000.00. Following the completion of the purchase, the director owned 6,149,096 shares in the company, valued at approximately $110,683,728. This trade represents a 77.00% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders purchased a total of 2,902,872 shares of company stock worth $53,769,784 in the last 90 days.

About Hemab Therapeutics

Hemab Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for people with serious bleeding and thrombotic disorders. The company’s research is centered on treatments designed to address diseases of the blood and coagulation system, with the goal of improving outcomes for patients who may not be adequately served by existing options.

Hemab’s pipeline includes drug candidates aimed at rare hematologic conditions, including factor XI-related approaches and other programs in inherited bleeding disorders.